Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wolk

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
Clinical Pharmacology and Therapeutics|May 9, 2017
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-AnalysisT Checchio, S Ahadieh, P Gupta, et al.
The British Journal of Dermatology|July 17, 2013
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatmentB Strober, M Buonanno, J D Clark, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2025
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label studyC Tziotzios, R Sinclair, A Lesiak, et al.
The British Journal of Dermatology|November 25, 2014
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trialR Bissonnette, L Iversen, H Sofen, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
The British Journal of Dermatology|September 7, 2018
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trialsB E Strober, A B Gottlieb, P C M van de Kerkhof, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp, A Menter, B Strober, et al.
Clinical Pharmacology and Therapeutics|May 9, 2017
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-AnalysisT Checchio, S Ahadieh, P Gupta, et al.
The British Journal of Dermatology|July 17, 2013
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatmentB Strober, M Buonanno, J D Clark, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2025
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label studyC Tziotzios, R Sinclair, A Lesiak, et al.
The British Journal of Dermatology|November 25, 2014
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trialR Bissonnette, L Iversen, H Sofen, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
The British Journal of Dermatology|September 7, 2018
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trialsB E Strober, A B Gottlieb, P C M van de Kerkhof, et al.
Pageof 4